Dupilumab had a fivefold improvement in sustained disease remission in bullous pemphigoid compared with placebo, along with a significant reduction in oral corticosteroid use.

Dupilumab significantly reduced airway inflammation in patients with uncontrolled, moderate-to-severe type 2 asthma. Read now.

With 30% of COPD cases misdiagnosed, experts call for improved diagnostic strategies, better disease classification, and ...

Abrocitinib was efficacious and safe in patients with atopic dermatitis who did and who did not respond to prior treatment with dupilumab.

Dupilumab rapidly treated and maintained improvements in lichenification, a type of skin thickening from repetitive ...

Some patients with psoriasis may have a super response to guselkumab, but questions remain regarding the generalizability of treatment strategies.

The Phase I trial will recruit approximately 98 healthy volunteers and adults living with atopic dermatitis at a single site ...

Across six asthma biologics, adherence differed by the therapy given and was often low or irregular based on three adherence measures, according to a presentation here.This cross-sectional cohort ...

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in ...

Learn how targeted therapy and advanced blood analysis transformed treatment for erthyroderma, a rare inflammatory skin ...

BLA accepted for review Dupilumab (Regeneron and Sanofi ... sNDA accepted AVB-114 (Avobis Bio) Stem cell therapy Treatment of perianal fistulas in patients with Crohn disease.